Bicycle Therapeutics (BCYC) Long-Term Debt Issuances (2021)

Bicycle Therapeutics posted quarterly Long-Term Debt Issuances of $15.0 million for Q1 2021.

Bicycle Therapeutics (BCYC) has 1 years of Long-Term Debt Issuances data on file, last reported at $15.0 million in Q1 2021.

  • For the quarter ending Q1 2021, Long-Term Debt Issuances changed N/A year-over-year to $15.0 million; the trailing twelve-month figure through Dec 2021 stood at $15.0 million (changed N/A YoY), and the FY2021 full-year result was $15.0 million, changed 0.0% from the prior year.
  • Long-Term Debt Issuances for Q1 2021 stood at $15.0 million.
  • Across five years, Long-Term Debt Issuances topped out at $15.0 million in Q1 2021 and bottomed at $15.0 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 2.73 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Bicycle Therapeutics 326.82 Mn 326.82 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2021 15.00 Mn
Mar 31, 2021 15.00 Mn